SCHEMBL3823910

SCHEMBL3823910

CCc1nccc(=O)[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4016016 0.83 PDE3B (0.51) —
SCHEMBL3639622 0.80 GPR84 (0.51) —
SCHEMBL28202924 0.80 — —
SCHEMBL791861 0.79 GPR84 (0.54) —
SCHEMBL10927286 0.78 — —
SCHEMBL14639314 0.78 — —
SCHEMBL6294711 0.78 GPR84 (0.38) —
SCHEMBL7257450 0.77 GPR84 (0.39) —
Hydrochloric Acid SCHEMBL30429172 0.77 GPR84 (0.37) —
SCHEMBL10431226 0.76 PDE3B (0.42) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106008362-B A kind of preparation method of pyrimidine derivatives 杰达维(上海)医药科技发展有限公司 2018-08-10 — — CN claimed
US-5869476-A ANGIOTENSIN II ANTAGONISTS; TREATING CARDIOVASCULAR DISORDERS BORYUNG PHARMACEUTICAL CO., LTD. (KR) 1999-02-09 — — US claimed
WO-2024035950-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-02-15 — — WO disclosed
WO-2023220428-A1 COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-11-16 — — WO disclosed
WO-2023028489-A1 COMPOSITIONS AND METHODS FOR TREATING PROTEOTOXICITY-ASSOCIATED DISEASES THE JOHNS HOPKINS UNIVERSITY (US) 2023-03-02 — — WO disclosed
WO-2020224656-A1 BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 劲方医药科技(上海)有限公司 2020-11-12 — — WO disclosed
CN-108395408-A A kind of pharmaceutical intermediate and preparation method thereof 杰达维(上海)医药科技发展有限公司 2018-08-14 — — CN disclosed
CN-106008362-B A kind of preparation method of pyrimidine derivatives 杰达维(上海)医药科技发展有限公司 2018-08-10 — — CN disclosed
EP-2498780-B1 N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE HOFFMANN LA ROCHE (CH) 2016-09-07 — — EP disclosed
EP-2499143-B1 N7-SUBSTITUTED PURINE AND PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE HOFFMANN LA ROCHE (CH) 2016-03-16 — — EP disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
US-20110086840-A1 N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2011-04-14 — — US disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 — — EP disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 — — EP disclosed
US-20090111822-A1 1,2,3-TRIAZOLE PYRROLIDINE DERIVATIVES AS MODULATORS OF MGLUR5 ASTRAZENECA AB (SE) 2009-04-30 — — US disclosed
EP-1646615-A1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2006-04-19 — — EP disclosed
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-03-17 — — US disclosed
WO-2004111014-A1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-12-23 — — WO disclosed
EP-0514192-A1 Antihypertensive benzofuran derivatives, substituted by varied N-pyrimidinyl- or N-imidazolyl-methyl groups GLAXO GROUP LIMITED (GB) 1992-11-19 — — EP disclosed
Send feedback